anti-CD3/anti-HER2 bispecific T-cell engager DARPin (Molecular Partners)

N/A

Report date: 2026/03/19 16:58:24

Base Information

Drug Nameanti-CD3/anti-HER2 bispecific T-cell engager DARPin (Molecular Partners)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Recombinant proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionT cell surface glycoprotein CD3 modulatorsReceptor protein-tyrosine kinase erbB-2 modulators

TargetsReceptor protein-tyrosine kinase erbB-2T cell surface glycoprotein CD3

Therapy Area/IndicationsLeukemia, Myeloid, AcuteNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySwitzerland

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesMolecular Partners Ag

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesMolecular Partners Ag

Active IndicationsN/A

Inactive IndicationsLeukemia, Myeloid, AcuteNeoplasms

Other Information

ATC CodeN/A